Received Dec 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | — | — |
Chronic lymphocytic leukemia/small lymphocytic leukemia; This literature-non-study case was reported in a literature article and describes the occurrence of CHRONIC LYMPHOCYTIC LEUKAEMIA (Chronic lymphocytic leukemia/small lymphocytic leukemia) in a 61-year-old male patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. LITERATURE REFERENCE: Concurrent medical conditions included Type 2 diabetes mellitus and GERD. On an unknown date, the patient received second dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHRONIC LYMPHOCYTIC LEUKAEMIA (Chronic lymphocytic leukemia/small lymphocytic leukemia) (seriousness criterion medically significant). At the time of the report, CHRONIC LYMPHOCYTIC LEUKAEMIA (Chronic lymphocytic leukemia/small lymphocytic leukemia) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy lymph gland: Biopsy of axillary lymph node was consistent with Chronic lymphocytic leukemia/small lymphocytic leukemia. On an unknown date, Computerised tomogram neck: CT with IV contrast revealed multiple enlarged axillary, mediastinal, retroperitoneal, cecal, periportal, peri pancreatic, and mesenteric lymph nodes. On an unknown date, Computerised tomogram thorax: CT with IV contrast revealed multiple enlarged axillary, mediastinal, retroperitoneal, cecal, periportal, peri pancreatic, and mesenteric lymph nodes. On an unknown date, Flow cytometry: showed 67% population of mature B lineage cells with CD45+, CD5+, CD9+, CD20+, CD3+, CD 38 Partial positive, HLA-DR+. For SPIKEVAX NOS (SPIKEVAX NOS) (Unknown), the reporter did not provide any causality assessments. Concomitant medication and treatment medication was not reported. Patient developed ipsilateral axillary lymphadenopathy (LAD) following a second dose of COVID-19 vaccination (mRNA-1273). He subsequently developed contralateral axillary LAD and supraclavicular LAD. He assumed this LAD was secondary to the vaccine and did not seek medical attention for approximately 3 years. At the time of presentation to clinic, he was also noted to have non tender occipital and cervical LAD. Throughout the course, his LAD had gradually increased in size but remained painless. He denied any B symptoms. He was referred to an oncologist, and he was undergoing a bone marrow biopsy as well as a positron emission tomography (PET) scan. He was being evaluated for a stem cell transplant at a tertiary oncology institution. Author concluded that mRNA COVID-19 vaccination had been implemented as a global health strategy to control the COVID-19 pandemic. It had been frequently associated with lymphadenopathy which typically resolves spontaneously. However, persistent lymphadenopathy should raise concern for other possible diagnoses such as Chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), a type of non-Hodgkin lymphoma, as seen in this patient.; Reporter's Comments: The benefit-risk relationship of product is not affected by this report.
GERD; Type 2 diabetes mellitus
Test Name: Biopsy of axillary lymph node; Result Unstructured Data: Biopsy of axillary lymph node was consistent with Chronic lymphocytic leukemia/small lymphocytic leukemia; Test Name: CT neck; Result Unstructured Data: CT with IV contrast revealed multiple enlarged axillary, mediastinal, retroperitoneal, cecal, periportal, peri pancreatic, and mesenteric lymph nodes; Test Name: CT chest; Result Unstructured Data: CT with IV contrast revealed multiple enlarged axillary, mediastinal, retroperitoneal, cecal, periportal, peri pancreatic, and mesenteric lymph nodes; Test Name: Flow cytometry; Result Unstructured Data: showed 67% population of mature B lineage cells with CD45+, CD5+, CD9+, CD20+, CD3+, CD 38 Partial positive, HLA-DR+